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Abstract: The biosynthesis of proteins entails a complex series of chemical reactions that transform 
the information stored in the nucleic acid sequence into a polypeptide chain that needs to properly 
fold and reach its functional location in or outside the cell. It is of no surprise that errors might occur 
that alter the polypeptide sequence leading to a non-functional proteins or that impede delivery of 
proteins at the appropriate site of activity. In order to minimize such mistakes and guarantee the 
synthesis of the correct amount and quality of the proteome, cells have developed folding, quality 
control, degradation and transport mechanisms that ensure and tightly regulate protein biogenesis. 
Genetic mutations, harsh environmental conditions or attack by pathogens can subvert the cellular 
quality control machineries and perturb cellular proteostasis leading to pathological conditions. This 
review summarizes basic concepts of the flow of information from DNA to folded and active 
proteins and to the variable fidelity (from incredibly high to quite sloppy) characterizing these 
processes. We will give particular emphasis on events that maintain or recover the homeostasis of the 
endoplasmic reticulum (ER), a major site of proteins synthesis and folding in eukaryotic cells. 
Finally, we will report on how cells can adapt to stressful conditions, how perturbation of ER 
homeostasis may result in diseases and how these can be treated. 
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1. Historical Considerations on Protein Synthesis 
Production of any protein requires that the information for the specific sequence of its amino 
acids is transcribed from DNA into an mRNA molecule. The mRNA will then be translated by the 
complex machinery of the ribosome and its co-factors into a polypeptide chain that must be folded, 
with assistance of chaperones and folding enzymes, in its unique architecture. First thoughts on the 
flow of genetic information were enounced by Francis Crick in 1956, when he exposed his “Ideas on 
protein synthesis” [1]. These were later published and partially revisited in a Nature article in 1970 
defining what he pompously (and inappropriately, as himself later admitted) defined as “Central 
dogma of molecular biology” [2] (Figure 1).  
 
Figure 1. The central dogma of molecular biology. Black arrows show the transfer of 
information as hypothesized by Francis Crick in 1970 [2]. Full arrows represent “general 
transfers”, dashed arrows represent “special transfers”. Shown in italic are the error rates 
for the biochemical steps involved in the synthesis from DNA to the native protein. 
Although the (mis) use of the word “dogma” generated some misunderstanding with colleagues, 
the principles he wanted to highlight were rather simple: once the information, intended as the 
sequence of amino acids in a protein is transferred from DNA into proteins, it cannot go back. In 
1970, Crick proposed a scenario where the flow of information would generally occur from DNA to 
DNA, DNA to RNA and from RNA to protein (what he called “general transfer”). RNA replication 
and flow of information from RNA to DNA and from DNA directly to protein were defined as 
“special transfers” meaning that they could happen under particular conditions. “Unknown transfers” 
were the ones from protein to protein as well as the reverse flow of information from protein to RNA 
or DNA. At the time, there were no experimental evidences for the latter and thus Crick 
hypothesized that these transfers were improbable to exist [2].  
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As science moved on, the concepts highlighted in Crick’s “central dogma” have dramatically 
changed and experimental evidences have proven the existence of “unknown transfers” such as 
reverse transcription (RNA to DNA) by Temin and Baltimore [3,4] and the description of the prion-
mediated inheritance [5].  
In any case, and independently of what Crick meant to say at the time he posted the “Ideas on 
protein synthesis” [1] and later on [2], it remains that translation and attainment of the correct ternary 
and quaternary structure of polypeptides are crucial steps in the flow of genetic information. Proteins 
are the active molecules that carry out almost every function in a living organism, while DNA stores 
the information to produce each one of them.  
2. The Ribosomal Machinery: from Nucleotides to Amino Acids 
Translation of genetic information (sequences of nucleotides) into a polypeptide chain 
(sequence of amino acids) is mediated by ribosomes. These are complex structures that act as RNA-
based enzymes (ribozymes) to catalyze peptide bond formation. Eukaryotic 80S ribosomes are large 
(4.3 MDa for the human ribosome) and complex structures composed of a large 60S subunit, which 
contains 47 proteins and 3 ribosomal (r)RNAs, and a small 40S subunit containing 33 proteins and  
1 rRNA molecule [6,7]. 
Translation can be divided in 3 steps: Initiation, elongation and termination (Figure 2).  
i) Initiation: Amino acids reach the ribosome conjugated with a specific transfer (t)RNA 
molecule (amino-acyl-tRNAs) that possesses a complementary anticodon for the codon encoding the 
specific amino acid. In eukaryotes, at least eleven different initiation factors are required to properly 
initiate translation. These ensure that the methionyl-initiator tRNA (Met-tRNAiMet) is brought in the 
P site of the ribosomal complex to the initiator AUG codon of an engaged mRNA [8] (Figure 2, step 1).  
ii) Elongation: Successive amino-acyl-tRNAs are recruited to the ribosome on the A-site 
(Figure 2, step 2). While the mRNA molecule is pulled through the ribosome, codon-matching 
amino-acyl-tRNAs are recruited one after the other in order to link the amino acids into a peptide 
chain. During elongation the tRNA is recruited to the A-site while an adjacent tRNA in the P-site is 
covalently bound to the growing amino acid chain (Figure 2, step 3).  
At this point a peptidyl transferase contained in the large ribosomal subunit breaks the high 
energy bond between the tRNA in the P-site and its amino acid, and links it to the free amino acid 
group on the tRNA in the A-site (Figure 2, step 4). This reaction causes a conformational shift of the 
large ribosomal subunit relative to the mRNA (which is bound by the small ribosomal subunit) 
leading to the shift of the bound tRNAs from the P- to the E-site and from the A- to the P-site (Figure 
2, step 5). Next, the small ribosomal subunit undergoes a conformational change and moves, together 
with the mRNA, exactly 3 nucleotides. This resets the ribosomal structure leaving an empty A-site 
that can now accommodate the next complementary amino-acyl-tRNA, which binding will lead to 
the release of the “empty” tRNA from the E-site (Figure 2, step 6) [9]. 
iii) Termination: Translation gets terminated when a stop codon (UAA, UAG or UGA) is 
encountered by the A-site of the ribosome. These codons stop translation by engaging so called 
release factors that bind the A-site and force the peptidyl-transferase to catalyze the addition of a 
water molecule to the C-terminal peptidyl-tRNA thereby releasing the carboxyl terminus from its 
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tRNA and leading to the disassembly of the large and small subunits of the ribosome (Figure 2,  
step 7) [10]. 
 
Figure 2. The ribosomal machinery. Schematic representing the steps of translation. 
Shown is also the aminoacyl-tRNA loading process by the tRNA-synthetase and its error 
rate. 
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Translation is a rapid process. The catalytic activity of the ribozyme elongates the polypeptide 
chain at a rate of 3–10 amino acids per second in eukaryotes [11,12] and up to 10–20 amino acids per 
second in E. coli [13,14,15].  
Every step in the biosynthetic process of proteins from DNA replication to protein folding 
(including transcription, amino-acyl-tRNA synthesis and translation) is error prone. Following 
chapters will focus on the fidelity of the mentioned processes and on quality control and repair 
mechanisms that operate in order to minimize the insertion of errors in the flow of genetic 
information from DNA to the mature protein. We will also discuss how cells maintain proteostasis i.e., 
how they ensure production of the proteome in correct amount and appropriate quality. 
3. Fidelity of Genetic Information Flow: Error Prone Steps and Dedicated Quality Controls 
3.1. Replication: from DNA to DNA 
DNA replication is performed with very high fidelity since the correct maintenance of the 
genetic material is fundamental for the survival not only of organisms but, most importantly, for 
species. DNA polymerases (the enzymes that catalyze the synthesis of new DNA strands) and their 
co-factors have evolved in order to minimize the insertion of wrong nucleotides. In fact, DNA 
replication machineries are estimated to insert a mismatched base every 104–105 nucleotides, but 
through the combined actions of proofreading and post-replication mismatch repair mechanisms, 
eukaryotic cells can replicate their genome with remarkable fidelity of less than 1 mutation per 
genome per cell division (error rate of 10–8–10–10) [16–20] (Figure 1). Although DNA replication 
error rate is exquisitely low, nucleotide mis-incorporation is fundamental for adaptation to changing 
environmental conditions and for driving evolution [20]. 
3.2. Transcription: from DNA to mRNA 
mRNA is the principal template molecule used for protein synthesis. Genes encoded in genomic 
DNA are transcribed, in the nucleus, by multi-component transcription machineries, which comprise 
RNA polymerases (RNA pol) as principal component, into a “transient” single stranded nucleotides 
chain (mRNA). This is transported into the cytosol where it can be engaged by the ribosomes (for 
reviews see [21,22,23]). The mRNA molecule has a relatively short half-life (around 9 h) and is re-
synthesized constantly (typically 17 copies/gene are present) [24]. The continuous renewal of the 
mRNA pool implies that errors during transcription have less severe consequences than errors 
occurring during DNA replication and also fidelity of the process is less stringent (about 1 wrong 
nucleotide every 104–106 bases both in vitro and in vivo) [25,26,27] (Figure 1).  
3.3. Translation: from mRNA to proteins 
When it comes to translation of mRNA polynucleotides into amino acid chains, the error rate 
increases. Generally, the error rate for translation is one order of magnitude higher than that for 
transcription, laying between a wrong amino acid every 103–105 codons [28–32] (Figure 1). An 
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evolutionary interpretation for the lower error rate in transcription than in translation is that an error 
in transcription would lead to many erroneous protein copies (on average 17 mRNA/gene code for 
50,000 proteins/gene [24], meaning ca. 2950 proteins/mRNA), whereas an error in translation affects 
only one polypeptide chain if the error is due to stochastic mis-incorporation (and not a defective 
machinery). Note that in addition to the mistranslation of mRNAs, the protein synthesis efficiency 
can also be hampered by the incorrect charging of the tRNAs themselves. Incorporation of the wrong 
amino acid on a given tRNA has been measured to occur with error rates of 10–4–10–5 [28] (Figure 2).  
3.4. Folding: from a sequence of amino acids to an active protein 
Protein biogenesis is not terminated upon translation. Most proteins must achieve a specific 
three dimensional structure, which is determined by its amino acid sequence. The final, or native, 
conformation of a polypeptide chain is generally the one that minimizes its free energy and can occur 
naturally in a test tube [33]. In the living cell, however, the polypeptide chain emerging from 
ribosomes has to undergo an active, chaperone-assisted process of folding (see 4.2), and in some 
cases of oligomerization, i.e., of pairing with other polypeptide chains, in order to achieve its 
functional conformation (tertiary and quaternary structures). Only then, proteins can be transported 
to their final destination. As one can imagine, the process of folding is all but error-free and needs 
strict quality assessment in order to permit the synthesis of a functional proteome.  
The efficiency of polypeptide folding, as well as the rate, varies substantially for different gene 
products. Intuitively, short, single domain proteins achieve their native structure rapidly and 
efficiently, whereas long, multidomain and multi-subunit complexes have folding pathways that can 
be aborted at any time. Moreover, efficiency and rate of folding are substantially affected or even 
fully blocked by mutations in the polypeptide chain or by perturbation of the environmental and 
homeostatic conditions of the folding environment (e.g., the ER) making it very difficult to make 
trustable predictions (Figure 1). As such, although it is generally thought that the folding process is 
efficient for most proteins [34,35] there are controversial results/opinions. For example a study 
reported that ca. 30% of the newly synthesized proteome was rapidly degraded by the proteasome as 
a possible indication of low efficiency [36], whereas another reported diametrically different 
conclusions [37].  
3.5. Targeting: the right protein in the right place 
In order to perform their functions, proteins and protein complexes must be transported to the 
right intra- or extra-cellular place. Protein targeting is as important as any other step in protein 
synthesis and as such, defect in protein localization have been linked to several medical conditions or 
diseases [38]. Approximately half of the synthesized cellular proteins need to be transported across 
or into a membrane [39] and regulation of most trafficking processes is based on specific signal 
sequences displayed by the polypeptide chains [40]. Protein transport within cells is carried out by 
both bulk (e.g., unselective ER export via COPII vesicles) and specific, receptor based mechanisms 
that enrich select cargos into COPII vesicles (e.g., ERGIC53-based export of secretory glycoproteins 
from the ER) [41,42]. Protein translocation across organelle membranes might happen post-
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translationally, as for mitochondrial, peroxisomal, secretory and nuclear proteins, or co-
translationally, as in the case of proteins of the secretory pathway and integral membrane proteins, 
which are synthesized directly into the ER. Protein trafficking into organelles involves specific 
mechanisms for each compartment. As a general rule, proteins carry a specific address tag for the 
organelle they are sent to. This tag is recognized by a receptor (bound on the organelle membrane or 
soluble), which engages the necessary import machinery. Protein import is energy driven and occurs 
through membrane-spanning channels (e.g., the TOM and TIM complexes of the outer and inner 
mitochondrial membrane [43] or the Sec61/Sec62/Sec63 complex of the ER membrane [44]). In the 
case of the nuclear envelope, small proteins up to 40 kDa can also traffic by simple diffusion [45]. 
The signal sequence may, or may not be removed upon translocation by signal peptidases. Studies on 
the fidelity of the cellular trafficking processes have not been performed, but several factors have 
been shown to be important and their loss significantly affects transport efficacy and precision and 
ultimately leads to disease [38]. As an example, two distinct mutations in the ERGIC-53 gene were 
shown to underlie the autosomal recessive bleeding disorder caused by combined factor V and factor 
VIII deficiency. Homozygous patients completely lack the expression of coagulation factors V and 
VIII due to their impaired export from the ER via COPII vesicles [46,47]. 
4. Dedicated Quality Control Mechanisms Monitor the Biosynthesis of Proteins 
Protein folding occurs in cellular compartments with different chimico-physical properties (i.e., 
cytosol, mitochondria, ER), which contain compartment-specific chaperones and enzymes that 
maximize protein folding efficiency. Cells have developed dedicated mechanisms that screen the 
quality of the proteome during its synthesis and intervene when a protein is not able to reach its 
native conformation by promoting degradation of the erroneous product. Degradation of cellular 
proteins generally occurs in the cytosol and nucleus via the ubiquitin proteasome system (UPS) [48–52] 
and additionally by lysosomal pathways upon engulfment of the cytosolic proteins or organelles by 
the process of autophagy [51,52,53]. Following chapters will describe quality control and 
degradation machineries that act during the proteins synthesis process, from translation to protein 
folding and secretion. 
4.1. Ribosome quality control complex (RQC) 
The quality of newly synthesized proteins is constantly monitored from the moment they start 
emerging from the ribosome up to their degradation [54]. The earliest defective ribosomal products 
(DRiPs) can be selected for degradation when they are still emerging from the ribosome. This 
mechanism of co-translational degradation takes place when the translation machinery is defective or 
engages faulty mRNAs, which leads to ribosomal/translational stalling and the formation of 
incomplete nascent chains (Figure 3).  
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Figure 3. The ribosome quality control (RQC). Stalled ribosomes are engaged by the 
RQC components, which mediate the mRNA independent addition of Ala and Thr 
extensions, followed by ubiquitination and degradation of the stalled nascent chain. 
Recent work in yeast showed that stalled 80S ribosomes carrying unfinished polypeptide chains 
are engaged by the ribosome quality control complex (RQC) which mediates ubiquitination and 
degradation of the incomplete nascent chain [55–58]. Molecular components of the RQC are the E3 
ubiquitin ligase Listerin (Ltn1), Tae2, Rqc1, Rqc2 and Cdc48 with its cofactors Ufd1 and  
Npl14 [55,59]. Importantly, a recent study described a novel mechanism by which the RQC, in 
association with the 60S ribosomal subunit, adds polypeptide stretches to the stalled nascent chain 
and eventually ubiquitinates and targets the polypeptide for degradation via the proteasome [59] 
(Figure 3). In particular, ribosome stalling leads to the dissociation of the 60S and 40S subunits 
(Figure 3, step 1), followed by association of Ltn1 and Rqc2 with the peptidyl-tRNA-60S species 
(Figure 3, step 2). Here Rqc2 through binding of Alanyl- and Threonyl-tRNA orchestrates the, nota 
bene mRNA free and 40S free, incorporation of carboxy-terminal Ala and Thr extension (termed 
CAT tails) into the incomplete protein, followed by subsequent ubiquitination by Ltn1 (Figure 3, step 3) 
and extraction through the Cdc48 complex (Figure 3, step 4).  
4.2. A select example: protein folding and quality control in the ER 
The ER plays a crucial role in the maintenance of a quantitatively and qualitatively correct 
proteome. In fact, it is the organelle where the synthesis and folding of most membrane bound and 
secreted proteins (which make up ca. 1/3 of a cell’s proteome [60]) occurs (Figure 4). Most proteins 
that are synthesized into the ER (Figure 4, step 1) may be subjected to the addition of a complex 
glycan, composed of three residues of glucose, nine mannoses and two N-acetylglucosamines 
(Glc3Man9GlcNAc2) on side chains of asparagine residues in the sequon Asn-Xxx-Ser/Thr/Cys 
(Xxx all but Pro or Asp). N-glycosylation is catalyzed by a multiprotein complex 
oligosaccharyltransferase (OST) [61,62] (Figure 4, step 2). The attached sugar increases solubility of 
nascent and folding polypeptides since it shields hydrophobic regions. Moreover, it engages folding, 
quality control and degradation factors to determine the fate of the folding protein [62,63,64]. For 
non-glycosylated proteins the processes that regulate folding and degradation are far less known and 
thus not mentioned in the following chapters. 
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4.2.1. N-glycan dependent protein folding and quality control 
Early upon addition of the glycan, the outermost glucose is trimmed by the ER enzyme α-
glucosidase I. The di-glucosylated protein-bound oligosaccharide engages Malectin [65] (Figure 4, 
step 3) a type I membrane-bound ER lectin, which was shown to preferentially associate with 
misfolded proteins [66]. Malectin operates the first quality control checkpoint for sequestration and 
delivery of misfolded proteins for ER-associated degradation (ERAD, see below). Elimination of the 
second glucose by α-glucosidase II leads to association of the maturing protein with the lectins 
Calnexin (CNX) and Calreticulin (CRT), which in turn engage enzymes necessary for proper folding 
of the bound polypeptide: protein disulfide isomerases (PDIs) like PDI, ERp57, ERp44, TMX1[67] 
and others, and peptidyl-prolyl isomerases (PPIs) like cyclophilin B (CYPB) (for a review see [62]) 
(Figure 4, step 4). Trimming of the third glucose by α-glucosidase II releases the substrate from 
CNX/CRT (Figure 4, step 5). This is a crucial step in protein folding in the ER. In fact, if a protein 
collapses to its proper conformation after release from CNX/CRT, it will be transported through the 
Golgi apparatus to reach its final intra- or extra-cellular destination [41,62] (Figure 4, step 6). On the 
contrary, if a protein is still misfolded after release from Cnx/Crt there are two options: (1) the N-
glycans are re-glucosylated by the glucosyltransferase UGT1 and the polypeptide enters another 
round of folding in association with CNX/CRT (hence CNX/CRT cycle, [62,64,68]) (Figure 4,  
step 7), or (2) the N-glycans get further trimmed by ER mannosidases such as ER α1,2-mannosidase 
I [69], EDEM1 [70], EDEM2 [71] and/or EDEM3 [72,73]. Removal of the mannoses impedes the re-
glucosylation by UGT1 [70] and enables the recruitment of OS-9 and XTP3B [74,75], two lectins 
that deliver misfolded proteins to retro-translocation channels (dislocons) built around E3 ubiquitin 
ligases such as HRD1 and GP78 embedded in the ER membrane [76] (Figure 4, step 8). Proteins that 
escape retention-based quality control in the ER might be retained in post-ER compartments. This 
relies on the intervention of UGT1 and p97 as has recently been shown for proteins displaying 
ionizable residues in the intramembrane domain [77] (Figure 4, step 9). 
4.2.2. ER-associated degradation (ERAD) 
Since protein folding is liable to error and its efficiency differs from protein to protein, 
misfolded products constantly form in the ER. These must be rapidly eliminated to avoid the 
formation of toxic aggregates and disturbances of ER homeostasis. Misfolded proteins generally 
undergo selection for degradation via de-mannosylation of their N-glycans by EDEM proteins and 
associate with the ER lectins OS-9 and XTP3B [78]. As mentioned above, these two ERAD lectins 
act as shuttles that deliver the misfolded polypeptide to dislocons. Once there, misfolded proteins are 
retrotranslocated into the cytosol, poly-ubiquitinated by E3 ligases, extracted from the membrane by 
the AAA-ATPase p97 and its co-factors, and eventually targeted to the 26S proteasome for extensive 
proteolysis [78,79] (Figure 4, step 8). ERAD activity must be carefully regulated to prevent 
excessive or inefficient degradation, which can in turn result in the onset of loss- or gain-of-function 
disorders, respectively. Indeed, the turnover and the intracellular level of some ERAD factors such as 
EDEM1, OS-9 and SEL1L, is controlled in a post-translational manner through what has been 
defined as ERAD tuning [79,80,81]. 
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Figure 4. Folding and quality control of glycosylated proteins within the ER. N-glycans 
are attached to the nascent chains. Proteins that achieve their native conformation are 
exported and targeted to their site of activity. Misfolded proteins are recognized by the 
ER quality control (QC) and selected for degradation via ERAD. Aggregation prone 
misfolded proteins are also degraded by autophagy. 
4.3. The role of autophagy in degradation of misfolded proteins 
As mentioned above, degradation of misfolded translational products not only happens through 
the UPS, but also via autophagy. Autophagy is a cellular degradative pathway that removes proteins, 
aggregates and even entire organelles, by engulfing them into double-membrane vesicles (the 
autophagosomes) that then fuse with lysosomes containing hydrolases (Figure 4, step 9). There are 
several types of autophagy (e.g., macroautophagy, microautophagy and chaperone mediated 
autophagy (CMA), for a review see [82]). They are mediated by the autophagy-related genes (ATG) 
and their associated enzymes [83,84,85]. Autophagy was first studied as a response to starvation, but 
several lines of research in the last decades made it clear that autophagy exists in many flavors and 
plays crucial roles in cell and organelle homeostasis [86] and, as such, is involved in human health 
and disease [87].  
In line with this, the degradation of misfolded proteins through macroautophagy or both UPS 
and macroautophagy has been reported. Examples of disease-related proteins degraded via the 
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autophagic machinery are mutant Huntingtin (HTT) protein (Huntington’s disease) [88], α-synuclein 
(Parkinson’s disease) [89], Aβ and tau (Alzheimer’s disease) [90,91]. Other well-characterized 
autophagy substrate is the Z-variant of α-1-antitrypsin (ATZ) [92] and cystic-fibrosis conductance 
regulator (CFTR) aggregates [93].  
Although autophagic degradation of cytosolic components might happen stochastically as a 
bulk phenomenon, several types of highly selective autophagy have recently been described. 
Autophagy receptors are essential for such targeted degradation, which allow the recognition of the 
specific cargo and its coupling to the autophagic machinery [94]. Specific degradation of parts of the 
ER (and its content) have been shown to be crucial both during homeostasis [95] and recovery from 
an unfolded protein response (UPR, see below), during which excess ER chaperones and folding 
factors are degraded via the lysosome in a Sec62 dependent manner [96]. 
5. Keeping Protein Biosynthesis in Balance 
The maintenance of proteostasis is of fundamental importance for the integrity of cells and 
organisms. As described above, cells are equipped with quality control and clearance mechanisms 
that ensure removal of misfolded proteins. These machineries that work efficiently under 
homeostatic conditions might need to be adjusted to fluctuations in cargo load in order to permit cells 
to adapt to, and tolerate stressful stimuli. Mutated or defective gene products might lead to loss-of-
function or gain-of-toxic-function phenotypes. Fluctuations in protein synthesis due to environmental 
conditions or pathogen attacks can create conditions of overload of the quality control systems. 
Pathogens may subvert cellular proteostasis by hijacking the protein synthesis and quality control 
machineries for the purpose of their reproduction and immune escape [78,97,98]. In addition to 
quality control and degradation system for monitoring the quality of their proteome, cells have 
developed responses to various stresses in order to preserve and restore protein homeostasis. If 
maintenance or recovery of homeostatic conditions is not possible (i.e., in case of pathologies) and 
cellular viability is threatened, modulation of protein synthesis, protein folding, quality control 
and/or stress responses via chemical and biological compounds might be an efficient strategy to 
counteract these diseases. 
5.1. The unfolded protein response: modulation of protein synthesis and quality control 
A striking example of cellular stress response is the unfolded protein response (UPR) elicited by 
the accumulation of misfolded proteins in the ER (Figure 5). Since the flux of nascent chains into the 
ER is dynamic and might change due to fluctuating environmental conditions, genetic mutations and 
attack by pathogens, a cell has to tune the level of its folding, quality control and ERAD components 
in order to preserve the production of membrane and secreted cargo proteins. Such homeostatic 
control is achieved by the constant monitoring of “ER load” by ER membrane embedded stress 
sensors, namely inositol-requiring-protein-1 (IRE1), activating transcription factor-6 (ATF6) and 
protein kinase RNA (PKR)-like ER kinase (PERK). These sensors are activated upon accumulation 
of misfolded proteins in the ER and subsequently orchestrate a signaling cascade from the ER to the 
nucleus [99] (Figure 5).  
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5.1.1. IRE1 and ATF6: modulation of protein folding and ERAD capacity 
5.1.1.1. IRE1 
The IRE1 branch of the UPR is the most conserved (found in yeast, plants and  
metazoans [100,101]). IRE1 is a type 1 protein with a lumenal N-terminal domain and a cytosolic C-
terminal region that possesses kinase and RNase activities. Mammalian cells possess two homologs, 
namely IRE1α and IRE1β characterized by tissue-specific distribution. IRE1α is activated upon 
accumulation of misfolded proteins, which leads to its oligomerization, trans-autophosphorylation 
with consequent activation of its RNase domain. IRE1α signaling occurs via the cleavage of its 
principal substrate, XBP1 (X-box binding protein-1) mRNA (Figure 5). An unconventional splicing 
event leads to the excision of an intron and subsequent ligation leads to the formation of the XBP1s 
mRNA that translates into a potent bZIP transcription factor that upregulates transcription of ER 
quality control components and enzymes for lipid synthesis, which controls ER membrane  
expansion [102] (Figure 5). In addition to XBP1 splicing, IRE1 is responsible for the cleavage of a 
specific subset of mRNAs, mechanism termed Regulated IRE1-Dependent Decay (RIDD), leading to 
the reduction of ER cargo protein synthesis [103] (Figure 5). 
5.1.1.2. ATF6 
ATF6 is a metazoan specific stress sensor with a type II topology consisting of a luminal 
carboxyl-terminal stress sensing domain and a cytoplasmic amino-terminal bZIP transcription factor 
domain. Upon ER stress, ATF6 is transported to the Golgi apparatus, where it is sequentially cleaved 
by site 1 and site 2 proteases (S1P and S2P) leading to the release of the bZIP domain (ATF6f), 
which translocates to the nucleus and enhances transcription of ER quality control and ERAD 
components [102,104] (Figure 5). Interestingly, XBP1s and ATF6 upregulate UPR target genes with 
similar functions (e.g., chaperones and PDIs) and even share some of their targets, which 
upregulation mainly aims at enhancing folding and degradation capacity of the ER [102,105]. 
Additionally XBP1 is also a target gene of the ATF6 pathway, thus tightly linking the IRE1 and the 
ATF6 branches of the UPR. 
5.1.2. PERK 
The third branch of the UPR differs in its outcome compared to the IRE1 and ATF6 pathways. 
PERK is a type I membrane protein with a luminal stress sensing domain, similar to the one of  
IRE1 [106], and a cytosolic kinase domain. Upon activation by ER stress, PERK oligomerizes and 
phosphorylates itself and other targets. Importantly, PERK phosphorylates the α-subunit of 
eukaryotic initiation factor 2 (eIF2α) at Ser51, which results in a diminished global protein synthesis, 
thus reducing burden of ER cargo proteins [107]. Phosphorylation of eIF2α specifically upregulates 
the translation of activating transcription factor 4 (ATF4) from an open reading frame in its 5’ 
untranslated region [108,109]. Important among ATF4 target genes are activating transcription factor 
3 (ATF3), transcription factor C/EBP homologous protein (CHOP) and DNA damage–inducible 34 
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(GADD34). ATF3 targets both CHOP and GADD34 [110] (Figure 5). CHOP is a transcription factor 
responsible for the upregulated transcription of several apoptotic genes, while GADD34, induced late 
during ER stress, encodes a phosphatase, which counteracts eIF2α phosphorylation (reducing 
translational inhibition). Thus, the PERK pathway plays a dual role during UPR: induction of 
apoptosis if the ER stress cannot be resolved and recovery of protein synthesis if eIF2α 
phosphorylation is reduced via both reduction of ER stress (decreased PERK activation) and 
GADD34. Additionally, PERK phosphorylates NRF2 which induces genes responsible for 
antioxidant responses [111] (Figure 5). 
 
Figure 5. The unfolded protein response. The three ER membrane embedded stress 
sensors are activated upon accumulation of misfolded proteins. IRE1 and ATF6 induce 
the transcription of folding and ERAD factors in order to restore proteostasis. PERK 
reduces global translation. If ER stress is not resolved, apoptotic programs are activated. 
6. Pathological Conditions and Therapeutic Options 
Several cellular machineries ensure the synthesis of the proper amount and quality of the 
proteome. Moreover, quality control mechanisms operate at every stage of protein biogenesis in 
order to maintain proteostasis and to respond to perturbations of various origins by inducing stress 
responses.  
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6.1. Conformational diseases and chemical/pharmacological chaperones 
Mutations in the genome can give rise to ribosomal products that can elude the quality control 
systems. Amino acid substitutions in a newly synthesized polypeptide might destabilize the entire 
protein’s structure [112] causing protein aggregation and deposition (gain-of-toxic-function), or 
resulting in rapid degradation of the aberrant product (loss-of-function) [113,114,115]. Such 
pathological conditions are referred to as conformational diseases [114,116]. The aggregation or 
misfolding of a single species of proteins can affect maturation of other cellular proteins that follow 
or engage similar pathways. This means that defects in a single protein might spread to several other 
protein species and induce their misfolding and aggregation, thus harnessing the entire proteostasis 
network [117,118]. If activation of stress response pathways cannot re-establish proteostasis, 
consequences will be deleterious for single cells, organs and the entire organism.  
Therapeutic approaches are available to restore the folding of proteins or to inhibit their 
aggregation by delivering molecules that facilitate folding of mutant proteins, stabilize their structure 
or enhance their solubility. Chemical chaperones are membrane permeable molecules that may non-
selectively rescue the folding and functionality of mutant misfolded proteins [114]. Pharmacological 
chaperones, which have the same biological function, specifically bind only to certain proteins. The 
specificity makes pharmacological chaperones very suitable for clinical use [119,120,121]. 
6.2. Modulation of the UPR as treatment option for several diseases  
The importance of the UPR is underlined by its implication in many diseases. Cancer cells 
undergo somatic mutations that are not detected by their DNA damage machineries, which enable 
them to ignore growth control and disable apoptotic signaling. Especially solid-tumor cells, which 
are poorly vascularized, might also encounter other type of stresses such as hypoxia, nutrient 
deprivation and pH changes [122]. These conditions can alter ER homeostasis and interfere with the 
physiological protein folding environment leading to the activation of the UPR. Activation of the 
IRE1/XBP1s and the ATF6 branches has been shown in several cancer types such as breast  
tumors [123], hepatocellular carcinomas [124], gastric tumors [125] and several cancer cell  
lines [126]. ER chaperone levels were shown to correlate with tumor aggressiveness and alterations 
in reaction to chemical agents. It is not clear if apoptotic signaling induced by the UPR is escaped 
due to specific activation of the IRE1 and ATF6 branches or to inactivation of the apoptotic program. 
In any case, cytoprotective branches of the UPR enable cancer cells to produce and fold large 
numbers of the proteins that they produce. Thus inhibition of the UPR might be a promising way to 
treat some types of cancer [127]. 
In contrast, other conditions are linked to an insufficient activation of the UPR, meaning that 
induction of the UPR, especially the IRE1 and/or ATF6 branches, could increase ER protein folding 
and export capacity decreasing aberrant ERAD of unstable, mutant proteins, thus ameliorating loss-
of-function diseases such as cystic fibrosis or lysosomal storage diseases [128,129,130]. Similarly, 
increasing ERAD activity could attenuate the secretion of destabilized, aggregation-prone proteins as 
in the case of human amyloid diseases [113,131,132,133]. UPR signaling pathways are thereby 
promising targets for pharmacological intervention in a heterogeneous variety of human diseases. 
470 
AIMS Biophysics                                                        Volume 3, Issue 4, 456-478. 
Small molecules, which selectively activate or inhibit only one branch of the UPR have been 
described and successfully used to influence pathological states [134–138]. Most recently, ATF6 
specific modulators were described. Ceapins selectively inhibit the ATF6 pathway by blocking 
ATF6 delivery (and cleavage) to the Golgi apparatus [139,140]. Moreover, several ATF6 activators 
that enable the reduction of extracellular protein aggregates were described [141]. The palette of 
available chemical compounds offers the possibility to specifically modulate one or more branches 
of the UPR (at least in cultured cells) paving the road for the development of new therapeutic options 
for a variety of medical conditions including cancer and conformational diseases. 
7. Perspectives 
Maintenance of proteostasis is of fundamental importance for cellular viability. Through the 
combined action of a highly interconnected network of signaling pathways, which modulate gene 
expression, translation, protein folding, trafficking and degradation, cells tightly control the 
abundance and quality of the produced proteome and adapt it to stressful conditions. Nevertheless, 
pathological conditions, such as protein conformational diseases, may arise due to defective protein 
folding and transport.  
The social and medical impact of protein misfolding diseases (most often rare genetic 
conditions that affect children) highlight the importance of understanding basic molecular 
mechanisms of cellular functions. Common pathways can be engaged by gene products at the basis 
of completely different pathological phenotypes (e.g. cancer vs lysosomal storage diseases). It will 
therefore be crucial in future to continue working on mechanisms involved in protein folding, ERAD 
and UPR in order to describe new targets for pharmaceutical intervention. Several open questions 
remain to be answered: What are the chimico-physical features of a protein that determine the 
engagement of specific folding or clearance machineries? How important are certain mechanisms in 
different cell types or tissues and how differently are they regulated? Do cells experiencing stresses 
communicate with and influence surrounding cells/tissues? Which are the components involved in 
the recovery from stresses? Do cells remember experiencing stressful conditions in order to adapt to 
future insults (epigenetics)? And of course how can these pathways be targeted in order to restore 
proteostasis?  
To the latter question the recently developed clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas9 (CRISPR associated protein 9) gene editing technology seems very 
promising to correct gene defects [142]. Gene-editing as a therapeutic option has the advantage of 
eliminating the problem at its source, but what if the intervention causes unpredictable side effects? 
In contrast to pharmacologic interventions, whose use can be promptly interrupted in case of 
unwanted side effects, irreversibility is the major drawback in “genetic surgery”. Thus, basic 
research aimed at identify new possible targets regulating processes involved in protein biogenesis 
(in its larger meaning) remains of fundamental importance. 
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